Indutrade Agrees to Acquire Polish Life Science Firm Sinmed
Indutrade agreed to acquire all shares of Poland-based Sinmed, which has approximately PLN 50 million (SEK 130 million) in annual sales. Closing is subject to Polish competition authority approval and is expected in Q4 2026; the deal is seen as marginally EPS-positive.
Indutrade has agreed to acquire all shares in Poland-based Sinmed, which generates annual sales of approximately PLN 50M (SEK 130M). Completion is subject to approval from Poland’s competition authority and is expected in Q4 2026. The acquisition is expected to have a marginally positive effect on EPS.